⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
HUYABIO International Delivers Significant Landmark Phase 3 Results in Advanced Melanoma
prnewswire.com
NVO
Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape
globenewswire.com
AMGN
AZN
JNJ
NVS
ABBV
AKBA
ARDX
CHNR
LLY
FGEN
GILD
GSK
NVO
PFE
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO
Pharmaceutical Regulatory Affairs in the Middle East and North Africa: Online Course Delivers Country-by-Country Regulatory Mastery Across the Region
globenewswire.com
NVO
Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
globenewswire.com
NVO
AI Revolutionizes Cardiovascular Drug Development with $1.4+ Billion in Strategic Investments
globenewswire.com
NVO
PFE
AZN
LLY
NVS
JNJ
MRK
SNY
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
prnewswire.com
NVO
EOLS
ABBV
CNXU
Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight
prnewswire.com
AMRX
NVO
AMGN
REGN
GSK
SNY
AZN
PFE
BMRA
MRK
A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It
prnewswire.com
NVO
ABBV
CNXU
LLY
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO